Building a world where
tomorrow is another day!

Home
サブ-ナビゲーション
  • Company
  • Science/Pipleline
  • News
  • Investor Relations
  • Career
  • Contact
  • Privacy Policy
  • Term of use
  • Sitemap

Home

News

  • Jan 27, 2026 Chordia Therapeutics Publishes Phase 1 Results of CLK Inhibitor Rogocekib for R/R AML/HR-MDS in Blood Advances (Follow-up announcement) pdf (346KB)
  • Jan 14, 2026 Non-consolidated Financial Results for the Three Months Ended November 30, 2025 pdf (441KB)
  • Jan 05, 2026 Yoshiyuki Tanaka appointed Chief Medical Officer (CMO) pdf (275KB)
  • Dec 12, 2025 By FISCO Corporation Notice of Distribution of Our Corporate Research Report pdf (269KB)

View All

Science

Science

Science

Development Pipeline

Development Pipeline

CLK Inhibitor CTX-712

CLK Inhibitor CTX-712

MALT1 Inhibitor CTX-177

MALT1 Inhibitor CTX-177

CDK12 Inhibitor CTX-439

CDK12 Inhibitor CTX-439

GCN2 Inhibitor CRD-1968099

GCN2 Inhibitor CRD-1968099

View All

Investor Relations
Investor Relations

Company

Corporate Name Chordia Therapeutics Inc.
Foundation November 1, 2017
Head Office 26-1, Muraoka-Higashi 2-chome,Fujisawa, Kanagawa 251-0012 Japan MAP
Tokyo Office 3-11-5,Nihonbashi-honcho,Chuo-ku,Tokyo 103-0023 Japan
Representative Hiroshi Miyake, Ph.D. CEO

Mission

Message

Leadership
Team

Career

People

People

Contact

Contact

ページの先頭へ
ページの先頭へ
  • footer-content
  • menu
  • gnavi-box